EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD

MINUTES OF THE MEETING HELD ON WEDNESDAY 20TH JUNE 2018 AT
12.30pm

IN SEMINAR ROOM 2, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL

PRESENT:
Dr L Rogan (LR)  Associate Director of Medicines, Research and
Clinical Effectiveness NHS EL CCG (Acting Chair)
Mrs C Woffindin (CW)  Medicines Information Manager, ELHT
Mr N Fletcher (NF)  Director of Pharmacy ELHT
Mrs C Dugdale (CD)  Meds Management Pharmacist NHS BwD CCG
Mrs L Holden (LH)  Pharmacist LCFT (representing Ms S Ramdour)
Mr J Vaughan (JV)  Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)  Clinical Commissioning Group MM Lead, GP EL

In Attendance
Ms L Prince  Medicines Management Technician EL CCG

2018/094: APOLOGIES:
Dr D Gavan (DG)  Consultant Radiologist ELHT
Mr V Goodey (VG)  Assistant Director of Pharmacy, Clin Service ELHT
Mr A Gray (AG)  Clinical Pharmacist, ELHT
Dr K Burch (KB)  Consultant Microbiologist ELHT
Dr T MacKenzie (TM)  GP, EL CCG

2018/095: DECLARATION OF INTEREST
None declared – relevant to agenda items.

2018/096: MINUTES OF MAY MEETING:
Accepted as a correct record.

2018/097: MATTERS ARISING:

2018/052: LMMG Recommendations (from Feb LMMG) - Melatonin guidelines –
awaiting updated guideline,
2018/073: Rifaxamin – Guidelines for Prescribing – Document to be updated and sent for comments from gastroenterology. Two issues require clarification: i. definition/threshold of ‘recurrent’ eg. One or more episodes. ii. length of treatment course.

**ACTION:** Updated document to be sent for comment to gastroenterology.

2018/085: LMMG Recommendations (from Apr LMMG) – DMARDs Shared Care Agreement Form – VG has held a meeting with rheumatology who will trial the letter/form. It will be set up as a template on the electronic letter system and progress will be fed back at next meeting. Other directorate will be involved when methodology worked out.

2018/088: OTC Guidance for CCGs – Joint Formulary is being updated to incorporate NHSE Policy on Self-Care. Recommendations need to include information on admission and discharge to ensure consistency of message and managing patient expectation. Prescribing of vitamin D for maintenance in children needs to be included as Paediatricians are still requesting GPs to prescribe.

**2018/098: NEW PRODUCT REQUEST – ULTIBRO® BREEZHALER**

Requested by Dr Hafeez, Respiratory Consultant, as a LABA/LAMA combination inhaler to include for COPD. It is a dry powder inhaler which would offer continuing on a dry powder device for those who need to progress from single agent dry powder device. ELMMB agreed to include on formulary and as option on the Guidelines for the Management of COPD when progress to a LABA/LAMA combination is required.

**Resolved: Ultibro® Breezhaler to be included on formulary and on COPD management guidelines.**

**Traffic Light: GREEN**

**2018/099: NEW PRODUCT REQUEST – CHLORAMPHENICOL EYE DROPS EYKAPPO®**

Eykappo® is requested by Mr Shankar, Ophthalmology Consultant, for use post operatively after glaucoma/corneal surgery when preservative free chloramphenicol eye drops are required for three weeks. Eykappo® is preservative free chloramphenicol in a bottle with an expiry 28 days from opening. It will be more cost effective when compared to chloramphenicol single dose preservative free eye drops for a course of treatment that is required for longer than 5 days. Eykappo® is approved for inclusion on formulary when chloramphenicol preservative free eye drops are required for longer than 5 days treatment.

**Resolved: Eykappo® to be included in formulary.**

**Traffic Light: RED**

**2018/100: LMMG CONSULTATIONS (for July LMMG)**

**NRT Position Statement update** – to retain existing local policy which includes helpful contact details. ELHE local policy to be checked against SPC and service provision.

**Evolocumab for Prevention of Events** – the Amber recommendation is not supported for the following reasons

- There is a patient access scheme with evolocumab
- GPs are not familiar with the product
- Evidence for use in this group is not strong
- Potential numbers are significant
- Arrangements are currently through homecare for NICE indications.
A full pathway is requested to restrict routine use and ensure prescribing is for exceptional cases.

**Denosumab for Corticosteroid induced Osteoporosis** - recommendation of Black is not supported. It should be a second line option in a treatment pathway after alendronate as it is for other groups of patients with osteoporosis.

Resolved: Comments to be sent to LMMG

**2018/101: LMMG RECOMMENDATIONS (from May LMMG)**

**Lisdexamphetamine Recommendation** – accepted as written for use in ELHE.

**Ivabradine Prescribing Information Sheet** - accepted as written for use in ELHE.

**Psoriasis Biologic & High Cost Drug Pathway – updated** - accepted as written for use in ELHE.

**Primary Care Constipation Guidelines - updated** – accepted as written for use in ELHE.

**2018/102: FORMULARY UPDATES**

**Sereflo (salmeterol & fluticasone) MDI** – more cost effective than current salmeterol & fluticasone combinations. Add to formulary (consider rationalising choice of products for this combination)  
Traffic light: Green

**Bismuth subsalicylate 262.5mg (Pepto-Bismol) for H pylori** - agreed for two patients who have failed standard therapy. A formulary request is required for consideration to include in routine therapy.

**Prempak C** – removed from formulary as product discontinued

Resolved: Formulary to be updated as above

**2018/103: ORAL ANTICOAGULANTS IN AF PRESCRIBING GUIDE – RENAL INFORMATION**

The ‘Oral anticoagulants in AF prescribing guide’ requires the use in renal impairment updating to include using ideal body weight in calculation of creatinine clearance. This was agreed and document to be updated.

It was noted that the document ‘Pathway for the Prevention of stroke and systemic embolism in non-valvular atrial fibrillation’ was issued by LMMG and this was intended to replace the prescribing guide (although this was not clear when it was issued). The documents are different and it was agreed to keep both on the website while seeking clarification.

2018/104: MHRA DRUG SAFETY UPDATE – VALPROATE PREPARATIONS
The MHRA have made materials available to support the Pregnancy Prevention Programme with Valproate preparations. Clinicians involved with prescribing valproate preparations need to be aware of programme and review all females of child bearing age still taking valproate. CCGs are concerned that new patients (children) are still being started on valproate – to be flagged with prescribers.
Resolved: MHRA Valproate documents available.

2018/105: NICE RECOMMENDATIONS (from May & fast track from June)
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy [TAG 520] is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned
Traffic Light: RED

Guselkumab for treating moderate to severe plaque psoriasis [TA521] is recommended as an option by NICE. Approved in line with NICE.
CCG Commissioned – Bluteq form
Traffic Light: RED

Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [TA525] is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned
Traffic Light: RED

2018/106: EAMS RECOMMENDATIONS
Nivolumab - Treatment as monotherapy of adult patients with advanced or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma after two or more prior systemic therapies.

Raxone 150 mg film-coated tablets (idebenone) - As treatment for slowing the decline of respiratory function in patients with Duchenne Muscular Dystrophy (DMD) from the age of 10 years who are currently not taking glucocorticoids.

Volanesorsen 300 mg Solution for Injection - As an adjunct to diet for the treatment of adult patients with familial chylomicronaemia syndrome.

STANDING ITEMS

2018/107: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – May 2018
Minutes acknowledged

2018/108: FOR ACTION/INFORMATION: LANCASHIRE CARE FT D & T MINUTES – May 2018
Minutes acknowledged
2018/109: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – May 2018
Minutes acknowledged

DATE OF NEXT MEETING – Wednesday 18th July 2018 12.30pm, Seminar Room 6, Learning & Development Centre, RBH.
### Action Sheet from East Lancashire Health Economy Medicines Management Board

**Wednesday 20th June 2018**

<table>
<thead>
<tr>
<th>Minute Number</th>
<th>Description</th>
<th>Action</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018/052</td>
<td>LMMG Recommendations (from Feb LMMG) Melatonin guidelines – ELHT guideline to include beneficial response information from LCFT guidance.</td>
<td>Dr Perera</td>
<td>May 18</td>
</tr>
<tr>
<td>2018/073</td>
<td>Rifaxamin – Guidelines for Prescribing – Updated document to be sent to gastroenterology with questions for comments</td>
<td>LR/CW</td>
<td>Jul 18</td>
</tr>
<tr>
<td>2018/085</td>
<td>LMMG Recommendations (from Apr LMMG) - DMARDs Shared Care Agreement Form – task &amp; finish group to look at implementation to be set up</td>
<td>VG</td>
<td>Sept 18</td>
</tr>
</tbody>
</table>